Skip to main content
idi
Toggle navigation
0
You have 0 notifications
Site Visitor
Site Visitor
New To Inknowvation.com?
Register now to get an access to proprietary SBIR-STTR databases!
Registration is fast and free - start your access to business-actionable information today!
Login
Site Register
SBIR-STTR Award
You are here:
Home
Search Databases
Search SBIR-STTR Awards
SBIR-STTR Award
10
Attenuated Shigella as Vector for Helicobacter Vaccine
Award last edited on: 1/2/03
Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$86,331
Award Phase
1
Solicitation Topic Code
-----
Principal Investigator
William D Thomas Jr
Company Information
Acambis PLC
(
AKA
: OraVax Inc ~ Acambis Inc)
38 Sidney Street
Cambridge, MA 02139
(617) 494-7339
acambis@acambis.com
www.acambis.com
Location:
Single
Congr. District:
07
County:
Middlesex
Phase I
Contract Number:
1R43AI038124-01
Start Date:
00/00/00
Completed:
00/00/00
Phase I year
1995
Phase I Amount
$86,331
Our goal is to develop a live vector vaccine against Helicobacter pylori by expression of urease in attenuated Shigella flexneri 2A strains and testing the ability of these strains to induce a protective mucosal response against H. felis in mice. Helicobacter pylori ureases will be expressed in attenuated S. flexneri strains to assess the feasibility of Shigella as an oral vaccine vector. OraVax and others have demonstrated that oral immunization with H. pylori urease results in a protective response against H. felis infection in mice when administered along with Cholera Toxin as a mucosal adjuvant. Attenuated S. flexneri 2A (CVD1203) expressing urease will be constructed and used to immunize mice. Protective immunity to Helicobacter infection will be assessed by subsequent challenge with H. felis. These experiments will evaluate the use of a live vector approach to immunization against H. pylori as an alternative to toxic mucosal adjuvants. The results of these preliminary experiments will provide the basis for Phase II experiments using non-human primate models of Shigella and H. pylori to confirm the efficacy of live attenuated S. flexneri 2A strains as vaccine live delivery vectors.National Institute of Allergy and Infectious Diseases (NIAID)
Phase II
Contract Number:
----------
Start Date:
00/00/00
Completed:
00/00/00
Phase II year
----
Phase II Amount
----
×
Login to your account
Mail sent successfully.
Enter any username and password.
Username
Password
Remember me
Login
Forgot your username?
Click here for assistance
Forgot your password?
Request new password
Don't have an account?
Sign up
Forgot username?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.
Forgot password?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.